Key terms
About ILMN
Illumina, Inc. engages in the development, manufacturing, and marketing of life science tools and integrated systems for large-scale analysis of genetic variation and function. It operates through the Core Illumina segment, which serves customers in the research, clinical and applied markets fields, and enables the adoption of a variety of genomic solutions. The firm's products include instruments, kits and reagents, selection tools, and software and analysis. Its services include sequencing and microarray services, proactive instrument monitoring, and instrument services, training, and consulting. The company was founded by David R. Walt, John R. Stuelpnagel, Anthony W. Czarnik, Lawrence A. Bock, and Mark S. Chee in April 1998 and is headquartered in San Diego, CA.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest ILMN news
Apr 12
10:00am ET
Illumina $1B cash outlay for Grail divestment ‘better than fears,’ says Evercore
Apr 12
9:12am ET
Illumina Gains Approval for GRAIL Divestiture Plans
Apr 12
9:01am ET
Illumina’s planned divestment of GRAIL approved by European Commission
Apr 12
1:39am ET
Illumina (ILMN) Maintains Strong Guidance and Strategic Leadership Appointments
Apr 09
4:34pm ET
Illumina Announces Executive Shift and New CFO Appointment
Apr 08
9:45pm ET
RBC Capital Sticks to Its Buy Rating for Illumina (ILMN)
Apr 04
5:40am ET
Analysts Offer Insights on Healthcare Companies: Illumina (ILMN) and Humana (HUM)
Mar 22
7:17am ET
Illumina’s Stock Rating Maintained at Hold Amid Legal Uncertainties and Regulatory Challenges
Mar 21
9:56am ET
Early notable gainers among liquid option names on March 21st
Mar 21
8:51am ET
EU opinion could mean Illumina no longer required to fund GRAIL, says Guggenheim
Mar 20
9:38am ET
Illumina downgraded to Mixed from Positive view at OTR Global
Mar 19
9:55am ET
Early notable gainers among liquid option names on March 19th
Mar 19
5:50am ET
Analysts Conflicted on These Healthcare Names: Illumina (ILMN) and Elevance Health (ELV)
Mar 15
9:39am ET
China stimulus positive for GE HealthCare, tool companies, says Evercore ISI
Mar 12
2:06pm ET
Icahn drops threat to challenge Illumina board, Reuters reports
Mar 12
2:03pm ET
Icahn drops threat to challenge Illumina board, Reuters reports
Mar 11
2:40am ET
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Illumina (ILMN), MoonLake Immunotherapeutics (MLTX) and Wave Life Sciences (WVE)
Feb 26
9:55am ET
Early notable gainers among liquid option names on February 26th
Feb 21
6:10am ET
Analysts Offer Insights on Healthcare Companies: Illumina (ILMN) and Globus Medical (GMED)
Feb 15
7:20am ET
Analysts Offer Insights on Healthcare Companies: CSL (OtherCMXHF), SAGE Therapeutics (SAGE) and Illumina (ILMN)
Feb 14
10:50am ET
Illumina participates in a conference call with TD Cowen
Feb 14
4:55am ET
Illumina participates in a conference call with TD Cowen
Feb 13
10:49pm ET
Illumina participates in a conference call with TD Cowen
Feb 13
9:10pm ET
Analysts’ Top Healthcare Picks: Illumina (ILMN), IDEAYA Biosciences (IDYA)
Feb 13
5:10am ET
Illumina’s Resilience Amidst Challenges: A Buy Rating with a Focus on Long-Term Growth
Feb 09
9:26am ET
Illumina price target raised to $160 from $125 at Stifel
Feb 09
8:15am ET
Illumina Inc.: Steady Performance with Cautious Outlook Justifies Hold Rating
Feb 09
8:01am ET
Analysts Are Bullish on Top Healthcare Stocks: Denali Therapeutics (DNLI), Illumina (ILMN)
Feb 09
7:58am ET
Illumina price target raised to $150 from $144 at TD Cowen
Feb 09
7:46am ET
Illumina price target raised to $105 from $100 at BofA
Feb 09
7:22am ET
Analysts Are Bullish on Top Healthcare Stocks: Zimmer Biomet Holdings (ZBH), Illumina (ILMN)
ILMN Financials
Key terms
Ad Feedback
ILMN Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
ILMN Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range
